Last reviewed · How we verify
APG-1252
APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.
APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells. Used for Solid tumors.
At a glance
| Generic name | APG-1252 |
|---|---|
| Also known as | APG-1252 for injection, Pelcitoclax |
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | Bcl-2/Bcl-xL inhibitor |
| Target | Bcl-2, Bcl-xL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
APG-1252 selectively binds to Bcl-2 and Bcl-xL proteins, disrupting their anti-apoptotic function and leading to the activation of caspases and subsequent cell death in tumor cells.
Approved indications
- Solid tumors
Common side effects
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (PHASE1)
- A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients (PHASE1)
- A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors (PHASE1)
- APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- A Study of APG-1252 in Patients With SCLC or Other Solid Tumors (PHASE1)
- A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy (PHASE1, PHASE2)
- Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer (PHASE1, PHASE2)
- APG-1252 in Patients With SCLC or Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APG-1252 CI brief — competitive landscape report
- APG-1252 updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI